MGNX MacroGenics Inc.

MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2020 after the market closes on Tuesday, May 5, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 5, 2020 at 4:30 p.m. ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID 2993147.

The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at /events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Anna Krassowska, Ph.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,  
EN
28/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

 PRESS RELEASE

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics’ President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics’ manag...

 PRESS RELEASE

MacroGenics Announces Pausing of Enrollment of New Study Participants ...

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that ta...

 PRESS RELEASE

MacroGenics to Participate in the 8th Annual Evercore Healthcare Confe...

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section ...

 PRESS RELEASE

MacroGenics Reports Third Quarter 2025 Financial Results and Provides ...

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on ...

 PRESS RELEASE

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

MacroGenics to Participate in the Stifel 2025 Healthcare Conference ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of Mac...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch